kabutan

RaQualia Pharma Inc.(4579) Summary

4579
TSE Growth
RaQualia Pharma Inc.
791
JPY
-11
(-1.37%)
Apr 28, 3:30 pm JST
4.96
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
786
Apr 28, 9:48 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.01
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
798 JPY 5.00 USD
Previous Close Apr 27
802 JPY 5.03 USD
High Apr 28, 9:00 am
802 JPY 5.03 USD
Low Apr 28, 1:14 pm
782 JPY 4.91 USD
Volume
105,400
Trading Value
0.08B JPY 0.52M USD
VWAP
790.47 JPY 4.97 USD
Minimum Trading Value
79,100 JPY 496 USD
Market Cap
0.02T JPY 0.13B USD
Number of Trades
350
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
1,438
1-Year High Dec 2, 2025
41,024
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 2,559,600
Apr 17, 2026 0 2,527,800
Apr 10, 2026 0 2,414,300
Apr 3, 2026 0 2,393,300
Mar 27, 2026 0 2,424,100
Company Profile
RaQualia Pharma Inc. is a drug discovery venture company specializing in pain disorders. Its main revenue source is the out-licensing of intellectual property rights for drug candidates.
Sector
Pharmaceuticals
RaQualia Pharma Inc. is a research and development-oriented drug discovery venture with a business model focused on out-licensing intellectual property rights of novel drug candidates to pharmaceutical companies. The company conducts drug discovery research and development for high-need medical conditions, primarily in gastrointestinal and pain disorders. RaQualia Pharma Inc. pursues agile and flexible business activities, offering its entire research and development portfolio for out-licensing at various stages, from early exploration to clinical development. The company actively engages in open innovation-based research and development, addressing a wide range of disease areas through industry-academic collaborations. RaQualia Pharma Inc. has built a research and development portfolio comprising multiple projects, including out-licensing preparation programs, out-licensed programs, and collaborative research programs.